Evidence map›Paper›PMID 29127665›Full record

ArticleJournal of gastrointestinal cancer2019

Hepatocellular Carcinoma Surveillance-Experience from Croatian Referral Centre for Chronic Liver Diseases.

Matea Majerović, Mislav Jelaković, Marina Premužić, Ivana Knežević Štromar, Davor Radić, Marko Mance, Stjepko Pleština, Rajko Ostojić, Nadan Rustemović, Zeljko Krznarić

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Matea MajerovićDepartment of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.
Mislav JelakovićDepartment of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia. mislavjelakovic@gmail.com.ORCID http://orcid.org/0000-0003-3505-9101
Marina PremužićDepartment of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.
Ivana Knežević ŠtromarDepartment of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.
Davor RadićDepartment of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.
Marko ManceDepartment of Surgery, University Hospital Centre Zagreb, Zagreb, Croatia.
Stjepko PleštinaDepartment of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia.
Rajko OstojićDepartment of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.
Nadan RustemovićDepartment of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.
Zeljko KrznarićDepartment of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Kišpatićeva 12, 10000, Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFor patients at high-risk of developing hepatocellular carcinoma (HCC), biannual ultrasound surveillance has long been recommended, in order to detect the tumor in the early, potentially curative stages. However, globally reported HCC surveillance rates vary greatly, ranging from as low as 1.7 to as high as 80%. Our aim was to assess the utilization of surveillance with biannual ultrasound in high-risk Croatian patients and to identify the factors that impact the implementation of the recommended protocol.

methodsThis retrospective study included 145 newly diagnosed HCC patients in the period from January 2010 to September 2015. We identified low-risk and high-risk patients. The latter were further subdivided into the regular biannual ultrasound surveillance group and the non-surveillance group. The groups were compared according to demographic characteristics and BCLC stage at the time of HCC diagnosis.

resultsAmong 145 patients, 80 patients were classified as high-risk according to EASL criteria. During the relevant period, 28.7% underwent regular surveillance, while 71.25% did not. Younger patients were more likely to undergo surveillance (OR 0.935 CI 0.874-0.999; p = 0.05). The patients who underwent regular surveillance had a higher chance of being diagnosed at a curative stage (BCLC 0 or A) (OR 3.701 CI 1.279-10.710; p < 0.05).Gender was not a predictor of participation in the regular surveillance protocol. Among the high-risk patients who did not undergo regular surveillance, 56.1% were not aware of the chronic liver disease prior to the HCC diagnosis.

conclusionHCC surveillance is still underutilized in high-risk Croatian patients despite its obvious benefits possibly due to the untimely diagnosis of the chronic liver disease.

Indexed as

AgedCarcinoma, HepatocellularChronic DiseaseCroatiaFemaleHumansLiver DiseasesLiver NeoplasmsMalePopulation SurveillanceRetrospective StudiesUltrasonographyHepatocellular carcinomaSurveillanceUltrasonography

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.